|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Moving forward in the treatment of cholangiocarcinoma显示文摘Despite being the second most frequent primary liver tumor in humans,early diagnosis and treatment of cholangiocarcinoma(CCA)are still unsatisfactory.In fact,survival after 5 years is expected in less than one fourth of patients diagnosed with this disease.Rare incidence,late appearance of symptoms and heterogeneous biology are all factors contributing to our limited knowledge of this cancer and determining its poor prognosis in the clinical setting.Several efforts have been made in the last decades in order to achieve an improved classification/understanding with regard to the diverse CCA forms.Location within the biliary tree has helped to distinguish between intrahepatic,perihilar and distal CCA types.Sequence analysis contributed to identifying several characteristic genetic aberrations in CCA that may also serve as possible targets for therapy.Novel findings are expected to significantly improve the management of this malignancy in the near future.In this changing scenario our review focuses on the current and future strategies for CCA treatment.Both systemic and surgical treatments are discussed in detail.The results of the main studies in this field are reported,together with the ongoing trials.The current findings suggest that an integrated multidisciplinary approach to this malignancy would be helpful to improve its outcome. | Tommaso M Manzia Alessandro Parente Ilaria Lenci Bruno Sensi Martina Milana Carlo Gazia Alessandro Signorello Roberta Angelico Giuseppe Grassi Giuseppe Tisone Leonardo Baiocchi | 2021 | World Journal of Gastrointestinal Oncology2021，13，12： | 6 |
| 2 | Chronic rejection after liver transplantation:Opening the Pandora’s box显示文摘Chronic rejection(CR)of liver allografts causes damage to intrahepatic vessels and bile ducts and may lead to graft failure after liver transplantation.Although its prevalence has declined steadily with the introduction of potent immunosuppressive therapy,CR still represents an important cause of graft injury,which might be irreversible,leading to graft loss requiring re-transplantation.To date,we still do not fully appreciate the mechanisms underlying this process.In addition to T cell-mediated CR,which was initially the only recognized type of CR,recently a new form of liver allograft CR,antibody-mediated CR,has been identified.This has indeed opened an era of thriving research and renewed interest in the field.Liver biopsy is needed for a definitive diagnosis of CR,but current research is aiming to identify new non-invasive tools for predicting patients at risk for CR after liver transplantation.Moreover,the minimization or withdrawal of immunosuppressive therapy might influence the establishment of subclinical CR-related injury,which should not be disregarded.Therapies for CR may only be effective in the“early”phases,and a tailored management of the immunosuppression regimen is essential for preventing irreversible liver damage.Herein,we provide an overview of the current knowledge and research on CR,focusing on early detection,identification of non-invasive biomarkers,immunosuppressive management,re-transplantation and future perspectives of CR. | Roberta Angelico Bruno Sensi Tommaso M Manzia Giuseppe Tisone Giuseppe Grassi Alessandro Signorello Martina Milana Ilaria Lenci Leonardo Baiocchi | 2021 | World Journal of Gastroenterology2021，27，45： | 2 |
| 3 | Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis显示文摘 | Angelico F Burattin M Alessandri C | 2007 | Cochrane Database Syst Rev2007，24，00： | 1 |
| 4 | Hepatobiliary complications associated with total parenteral nutrition显示文摘 | Angelico M Della Guardia P | 2000 | Aliment Pharmacol Ther2000，14，2： | 1 |
| 5 | Insulin Resistance, the Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease显示文摘 | F Angelico M Del Ben R Conti S Francioso K Feole S Fiorello M G. Cavallo B Zalunardo F Lirussi C Alessandri F Violi | 2005 | The Journal of Clinical Endocrinology & Metabolism2005，，3： | 1 |
| 6 | Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis viruis factions显示文摘 | Angelico M Renganathan E Gandin C | 1997 | Hepatol1997，26，2： | 1 |
| 7 | Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis 显示文摘 | Angelico M Di Paolo D Trinito MO | 2002 | Hepatology2002，35，1： | 1 |
| 8 | Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis显示文摘 | ANGELICO F BURATTIN M ALESSANDRI C | 2007 | Cochrane Database Syst Rew2007，24，00： | 1 |
| 9 | Isosorbide-5- mononitrate versus propranolol in the prevention of first bleeding in cirrhosis显示文摘 | ANGELICO M CARLI L PIAT C | 1993 | Gastroenterology1993，104，： | 1 |
| 10 | Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases显示文摘 | Angelico F Del Ben M Conti R | 2003 | J Gastroenterol Hepatol2003，18，： | 1 |
| 11 | Effects of isosorbide- 5- mononitrate compared with propranolol on first bleeding and long- term survival in cirrhosis 显示文摘 | ANGELICO M CARLI L PIAT C | 1997 | Agaastroenterology1997，113，： | 1 |
| 12 | Failure of reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis显示文摘 | Angelico M Di Paolo D Trinito M O | 2002 | Hepatology2002，35，1： | 1 |
| 13 | In vivo, high field, 3 Tesla 1H MR spectroscopic assessment of liver fihro sis in HCV correlated chronic liver disease 显示文摘 | Orlacchio A Bolacchi F Angelico M | 2008 | Radiol Med2008，113，： | 1 |
| 14 | Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis显示文摘 | Angelico M Di Paolo D Trinito MO | 2002 | Hepatol2002，35，1： | 1 |
| 15 | Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases显示文摘 | ANGELICO F DEL BEN M CONTI R | 2003 | J Gastroenterol Hepatol2003，18，5： | 1 |
| 16 | Isosorbide--5- mononitrate versus prop- ranolol in the prevention of first bleeding in corrhosis 显示文摘 | Angelico M Carli L Plat C | 1993 | Gastroenterology1993，104，5： | 1 |
| 17 | A randomized study on peginterferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C 显示文摘 | Angelico M Petrolatil A Lionetti R | 2007 | J Hepatol2007，46，6： | 1 |
| 18 | Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV- related cirrhosis显示文摘 | Angelico M Di Paolo D Trinito MO | 2002 | Hepatology2002，35，1： | 1 |
| 19 | Insulin resistance,the metabolic syndrome,and nonalcoholic fatty liver disease显示文摘 | Angelico F Del Ben M Conti R | 2005 | J Clin Endocrinol Metab2005，90，3： | 1 |
| 20 | Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis显示文摘 | ANGELICO F BURATTIN M ALESSANDRI C | 2007 | Cochrane Database Syst Rev2007，24，00： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员